Journals / Meme Sağlığı Dergisi / 2010 / Cilt: 6 - Sayı: 2

Mastektomiden sonra adjuvan tedavi alan hastalarda izole lokorejyonel nüks

Isolated locoregional recurrence in patients with postmastectomy adjuvant therapy for breast cancer

Pages
53–61
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Tumor size, lymph node status, and closer surgical margin were found to be the independent factors influencing LRR-free overall survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To determine the predictive risk factors for isolated locoregional recurrence (LRR) in breast cancer patients with postmastectomy adjuvant therapy.
📊
Key Findings & Data:Results: Of 368 patients, 28 (7.6%) had isolated LRR.
💡
Conclusion & Impact:Tumor size, lymph node status, and closer surgical margin were found to be the independent factors influencing LRR-free overall survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To determine the predictive risk factors for isolated locoregional recurrence (LRR) in breast cancer patients with postmastectomy adjuvant therapy. Patients and Methods: The impacts of patients’ characteristics, tumor stage, and surgery on LRR were evaluated in patients with breast cancer having postmastectomy adjuvant therapy, according to their risk factors using univariate analysis. Factors influencing LRR-free survival were assessed by Cox regression analysis. Results: Of 368 patients, 28 (7.6%) had isolated LRR. Patients’ characteristics such as age, menopause, surgery, tumor size, stage and differentiation, and hormone receptor status were not attributable to LRR. Upper outer quadrant localization was significantly associated with lower LRR occurrence (p=0.048). Among 245 patients whose surgical margin could be assessed, LRR was detected in 6 (20%) of 30 patients with a close surgical margin, while of 215 patients with normal surgical margin, 13 (6%) developed LRR (p=0.007). Kaplan-Meier analysis revealed that larger tumor (p=0.04), presence of LRR (p=0.00001), closer surgical margin (p=0.0085), stage (p=0.0001), and presence of lymph node metastases (p=0.00001) have significantly negative impacts on patients’ survival. Tumor size, lymph node status, and closer surgical margin were found to be the independent factors influencing LRR-free overall survival. Conclusion: Postmastectomy LRR seemed to have a close relationship with the surgical margin status despite standard adjuvant treatments.

Özet

Giriş: Mastektomili hastalarda, adjuvan tedaviye rağmen lokorejyonel nüks (LRN) gelişiminde etkili prediktif risk faktörlerini belirlemek Yöntem ve Gereçler: Meme kanseri nedeniyle mastektomi uygulanan ve adjuvan tedavi alan hastalarda, yaş, menopoz durumu, tümörün çapı, evresi, cerrahi şekli, pozitif lenf nodu sayısı, cerrahi sınır uzaklığı, histolojik grade gibi faktörlerin izole LRN’e etkileri tek değişkenli testle, lokal nükssüz sağkalıma etkili faktörler ise Cox regresyon analizi ile incelendi. Bulgular:368 hastanın 28’inde (%7,6) izole LRN gelişti. Hastaların yaş ve menopoz gibi özellikleri, uygulanan mastektominin cinsi, hastalığın evresi, tümör çapı, aksiller lenf nodu durumu ile tümörün diferansiyasyonu, hormon reseptör durumu LRN üzerine etkili değildi. Tümörün üst dış kadranda yerleşiminde LRN daha az görülmekteydi (p=0,048). Cerrahi sınır uzaklığı kaydedilmiş 245 hastanın 30’unda cerrahi sınır yakındı ve bunların altısında (%20) LRN saptanırken, cerrahi sınırı normal olan 215 hastanın 13’ünde (%6) LRN gelişti (p=0,007). Kaplan-Meier analizinde, sağkalımı olumsuz etkileyen faktörler tümör çapının büyük olması (p=0,04), LRN gelişimi (p=0,00001), cerrahi sınır yakınlığı (p=0,0085), evre (p=0,0001) lenf nodu metastazı varlığıydı (p=0,00001). Tümör boyutu, lenf nodu durumu ile cerrahi sınır yakınlığı, lokal nükssüz sağkalımı etkileyen bağımsız faktörlerdendi. Tartışma: Cerrahi sınır yakınlığı, mastektomi sonrası LRN gelişiminde, adjuvan tedavilerden etkilenmeyen tek faktördür.

🔖

Cite This Article

YİĞİTLER, C., GÜLEÇ, B., YİĞİT, T., KOZAK, O., UZAR, A. İ. (2010). Mastektomiden sonra adjuvan tedavi alan hastalarda izole lokorejyonel nüks. Meme Sağlığı Dergisi, Cilt: 6 - Sayı: 2, 53–61. https://ajindex.com/articles/278241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Parker S, Tong T, Bolden S, et al. Cancer statistics 1996. CA 1996; 46:5. (PMID: 854526
  2. Yalçın A, Nevruz O, Arpacı F, et al. GATA Hastanesi 2001 malignite olgularının incelenmesi. Gülhane Med J 2003; 45: 196-200
  3. Sarrazin D, Le MG, Arriaga R, et al. Ten-year results of a randomized trial comparing a conservative management to mastectomy in early breast cancer. Radiother Oncol 1989; 14: 177-184. (PMID:2652199) 4. von Dongen JA, Bartelink H, Fentiman IS, et al. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial. J Natl Cancer Inst Monogr 1992; 11: 15-18 (PMID: 1627421)
  4. Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. J Natl Cancer Inst Monogr 1992; 11: 19-25 (PMID: 1627427)
  5. Veronesi U, Banfi A, Salvadori B, et al. Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial. Eur J Cancer 1990; 26: 668-670 (PMID: 2144152)
  6. Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years follow-up in a randomized clinical trial comparing total mastectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333: 1456-1461 (PMID: 7477145)
  7. Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995; 332: 907-911 (PMID: 7877647)
  8. Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small cancer of the breast: long-term results of three randomized trials on 1,973 patients. Eur J Cancer 1995; 31: 1574-1579 (PMID: 7488404). 10. von Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: EORTC 10801 trial. J Natl Cancer Inst 2000; 92: 1143-1150 (PMID: 10904087)
  9. Abrams JS, Phillips PH, Friedman MA, Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer. J Natl Cancer Inst 1995; 87(24): 1837-1845 (PMID: 7494227)
  10. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-1360 (PMID: 9747866)
  11. Paik S, Bryant J, Park C, et al. ErbB-2 and response to doxorubicin in patients with axill